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Practice guidelines deﬁne hemodialysis catheter dysfunction as blood ﬂow rate (BFR) <300mL/min. We conducted a study using
data from DaVita and the United States Renal Data System to evaluate the impact of catheter dysfunction on dialysis and other
medical services. Patients were included if they had ≥8 consecutive weeks of catheter dialysis between 8/2004 and 12/2006. Actual
BFR<300mL/mindespiteplannedBFR ≥300mL/minwasusedtodeﬁnecatheterdysfunctionduringeachdialysissession.Among
9,707 patients, the average age was 62,53% were female, and 40% were black. The median duration of catheter dialysis was 190
days, and the cohort accounted for 1,075,701 catheter dialysis sessions.There were 70,361 sessions with catheter dysfunction, and
6,33 1 (65.2%) patients had at least one session with catheter dysfunction. In multivariate repeated measures analysis, catheter
dysfunction was associated with increased odds of missing a dialysis session due to access problems (Odds ratio [OR] 2.50;
P<0.001), having an access-related procedure (OR 2.10; P<0.001), and being hospitalized (OR 1.10; P = 0.001). Catheter
dysfunction deﬁned according to NKF vascular access guidelines results in disruptions of dialysis treatment and increased use of
other medical services.
1.Background
Blood ﬂow rate (BFR) <300mL/min often is used to deﬁne
hemodialysis catheter dysfunction, including in the National
KidneyFoundation’s(NKF)KidneyDisease OutcomesQual-
ity Initiative (KDOQI) vascular access guidelines [1, 2], and
in many research studies [3]. Causes of catheter dysfunction
include mechanical kinking, malpositioning of the catheter
tip, thrombus accumulation, and growth of a ﬁbrin sheath
[4]. Early dysfunction, which has been deﬁned as occurring
withintheﬁrst twoweeksofplacement[2],ismost often,but
not exclusively, caused by mechanical problems. Delayed or
late dysfunction is typically caused by thrombus accumula-
tion, with or without the presence of a ﬁbrin sheath [4], and
is considered to be the most likely cause of low BFR overall
[4–7].
Other deﬁnitions of catheter dysfunction reported in
the literature include frequent arterial and venous pressure
alarms, poor conductance, and poor dialysis eﬃciency based
on urea reduction ratio or Kt/V calculations [4]: these have
been applied when evaluating the impact of catheter dys-
function on clinical outcomes, economic expenditures, and
patientqualityoflife [8–11].However,theimpact ofcatheter
dysfunction using a BFR threshold, such as in the NKF-
KDOQI guidelines, has received less attention. One notable
exception is a recent study examining the relationship
between hemodialysis catheter BFR and dialysis adequacy in
a cohort of 259 patients at two university-based centers [12].
T h ep r e m i s ef o rt h i ss t u d yw a st h a ts i n c et h eN K F - K D O Q I
blood ﬂow threshold for catheter dysfunction was opinion
based [1] and has been interpreted to mean that maintaining
BFR > 300mL/min is necessary for adequate dialysis, it is2 International Journal of Nephrology
important to better understand the association between BFR
and dialysis adequacy. The study found that mean BFRs
< 300mL/min were not commonly associated with dialysis
inadequacy,leadingtheauthorstoconcludethatstrict adher-
ence to the guideline could result in a signiﬁcant number
of unnecessary interventions. To our knowledge, however,
the impact of hemodialysis catheter BFR <300mL/min on
dialysis and other medical services has not been evaluated.
The objectiveofthisstudy was toidentify medical service
utilization, including missed sessions, access-related proce-
dures, and all-cause hospitalizations, associated with dialysis
catheter dysfunction deﬁned according to a BFR threshold
<300mL/min.
2.Methods
2.1. Study Design and Setting. We conducted a retrospective
cohort study using data from DaVita Inc. and the United
States Renal Data System (USRDS). DaVita serves approx-
imately 110,000 dialysis patients throughout the USA. The
DaVita clinical data warehouse is a repository for detailed
demographic, treatment, medication, and laboratory infor-
mation. Information is available for each patient’s individual
dialysis sessions, allowing the investigator to reconstruct
detailed longitudinal treatment histories.
The USRDS is a national data system that collects, ana-
lyzes, and distributes information about end-stage renal
disease (ESRD) [13]. The dataset includes the Centers for
Medicare and Medicaid Services’ (CMS), Renal Beneﬁciary
and Utilization System (REBUS), and the ESRD Standard
Analysis Files (SAF). REBUS contains demographic, diag-
nosis, and treatment history information for all Medicare
beneﬁciaries with ESRD, a point prevalent cohort of approx-
imately 570,000 in the second quarter of 2009 [14]. The
SAFs contain 100% of Part A and Part B institutional claims
and Part B physician supplier claims for these patients. The
dataset used in this project consisted of a point prevalent
dialysis patient populationin August 2004, with a maximum
followup period through December 31, 2006.
2.2. Participants. Patients were included in this study based
on the following criteria: they had at least eight continuous
weeksofhemodialysisexclusivelythroughacatheterbetween
August 1, 2004, and December 31, 2006; in the ﬁrst eight
weeks of catheter dialysis, they did not have a gap between
two consecutive outpatient dialysis sessions >30 days in
which they were not hospitalized; they had both Part A and
Part B Medicare coverage during the entire catheter dialysis
period; they did not have a kidney transplant during the
entire catheter dialysis period; at least 95% of their catheter
dialysis sessions had actual and planned BFRs between
100mL/min and 500mL/min; they were alive and in the
dataset for at least 90 days following the ﬁrst catheter dial-
ysis session (Figure 1). Planned and actual BFR values
<100mL/min or >500mL/min were set to missing to min-
imize the potential impact of coding errors. In the ﬁnal co-
hort, 99.9% of BFR values were within this range. Pa-
tients were followed from their ﬁrst catheter dialysis session
(deﬁned as their index date), to their last catheter dialysis
session that was uninterrupted by either a change in access
or dialysis modality. This was deﬁned as their observation
period.
2.3. Variables. For each patient included in the study, we
reconstructed a longitudinal history of catheter dialysis and
medical resource use during their observation period. Rea-
sons for reaching the end of the observation period were (i)
death, if the patient died on or before December 31, 2006,
and if the last catheter dialysis session was within 30 days of
death, (ii) end of data (censored), if the last catheter dialysis
session was within 30 days of December 31, 2006, or (iii)
changeinaccesstypeormodality,ifthelastobservedcatheter
dialysis session was notduetoeitherdeathortheendofdata.
Catheterdysfunction was deﬁned asactual BFR<300mL/
min despite a planned BFR ≥300mL/min. A slight modi-
ﬁcation of the NKF-KDOQI vascular access guideline was
adopted to eliminate misclassiﬁcation of catheter dysfunc-
tion where the intent, as indicated by planned BFR, was to
provide BFR <300mL/min. The outcome variables in this
study were dialysis run time (in minutes), missed dialysis
session due to access problems, access-related procedures,
and all-cause hospitalization. The DaVita data contained a
record for each missed session, which included the date and
the reason for the missed session, including “access prob-
lems.”Access-related procedureswere identiﬁed using Health
Care Common Procedure Coding System (HCPCS) codes
from Medicare claims. The “limited” deﬁnition of access-
related procedures consisted of the following: injection for
catheter evaluation with ﬂuoroscopy (36598); thrombolytic
declotting of catheter (36593); mechanical removal of clot
(36596); Mechanical removal of intraluminal (intracatheter)
obstructive material (75902); injection of “TPA” (J2997).
The “expanded” deﬁnition also included tunneled catheter
exchange or replacement (36581) and the combination of
removal of tunneled catheter (36589) plus tunneled catheter
insertion (36558).Hospitalizations consisted ofall acute care
admissions for any reason.
2.4. Analyses. We used two diﬀerent approaches to ana-
lyze associations between catheter dysfunction sessions and
economic outcomes: case-crossover [15]a n dm u l t i v a r i a t e -
repeated measures analysis. In the case-crossover analyses
(Figure 2), we included only patients who had the event of
interest (e.g., missed dialysis session due to access problem).
For each of these patients, we identiﬁed the ﬁrst event at
least six sessions following the beginning of catheter dialysis.
As shown in Figure 2, we divided the six dialysis sessions
immediately preceding the event into two exposure periods:
the case period was deﬁned as sessions 1–3 immediately
preceding the event, and the control period was deﬁned
as sessions 4–6 preceding the event. For each patient, we
identiﬁed the presence of at least one session with catheter
dysfunction within each of the two periods, case and
control. Patients were then divided into four groups, as
illustrated in the two-by-two table within Figure 2:c a t h e t e r
dysfunction in both periods (labeled “A” in the two-by-twoInternational Journal of Nephrology 3
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Figure 1: Patient inclusion and exclusion criteria.
table); no catheter dysfunction in either period (D); catheter
dysfunction in the case but not the control period (C);
catheter dysfunction in the control but not the case period
(B). The odds of the exposure (in this case, the presence of at
least one catheter dysfunction session) being associated with
the outcome of interest is deﬁned as the ratio of the count
of patients with a catheter dysfunction session in the case,
but not the control, period divided by the count of patients
withacatheterdysfunctionsession inthecontrol,butnotthe
case, period (C/B in Figure 2). As patients serve as their own
controls, there is no need to adjust this ratio for covariables.
We conducted a sensitivity analysis, where we changed the
lengths of the case and control periods from three sessions
each to one session each.
Multivariate-repeated measures analyses [16, 17]w e r e
used as the second approach. All patients in the catheter
dialysis cohort were included in these analyses, as were all of
theirsessions. Theseanalysesusedindividualdialysissessions
as the repeated measures and incorporated as covariables
patient age, gender, race, underlying cause of renal failure,
ESRD network, dialysis vintage, Charlson Comorbidity
Index [18], days since the start of catheter dialysis, and
whether the patient could have started catheter dialysis prior
to the beginning of the observation window. Each dialysis
session included a binomial outcome variable indicating
whether the outcome, for example, missed session due to
access problems, occurred between the date of the current
session and the date of the following session. Therefore,
the repeated measures analysis was designed to measure the
relative odds of the outcome occurring before the following
dialysis session, among those with versus without catheter
dysfunction inthe previous session. In additionto specifying
catheter dysfunction as a dichotomous variable (BFR <
300mL/min versus ≥300mL/min, the reference category),4 International Journal of Nephrology
SS S S S SD E
Four possibilities
Case period
D+
D+
D−
D−
A B
C D
Odds ratio = C/B
“D” indicates catheter dysfunction session
“E” indicates event (e.g., missed 
session due to access) Control period Case period
C
o
n
t
r
o
l
 
p
e
r
i
o
d
(1 per patient)
Figure 2: Case-crossover design.
we created ﬁve intervals of BFR (100–<150mL/min; 150–
<200mL/min; 200–<250mL/min; 250–<300mL/min; and
≥300mL/min, the reference category) and then repeated all
the multivariate analyses using this speciﬁcation instead of
the dichotomous speciﬁcation as the independent variable
f o rc a t h e t e rd y s f u n c t i o n .I nt h e se analyses, we also included
dialysis run time in minutes as an independent variable.
Analysis ﬁle construction, descriptive analyses, and the case-
crossover analyses were performed in SAS (version 9.1.3)
[19]. The repeated measures analyses were performed in
STATA (version 10) [20].
3.Results
Of44,470patients inthe combined DaVitaUSRDSdatabase,
9,707 (22%) met all the inclusion criteria (Figure 1). The
average age of the cohort was 62 years (range 18–102), 53%
were female gender, 40% were black race, 46% had diabetes,
28% had hypertension recorded as their underlying cause of
renal failure, and 63% had a Charlson Comorbidity Index of
≤2(Table 1).TheaveragedurationofESRDpriortoentering
the cohort was 40 months (range 0–367).
The median duration of catheter dialysis was 190 days
(Interquartile range 108–386 days). Reasons for the end of
catheter dialysis were as follows: 7,476 (77%) switched to
another dialysis access type or modality and 1,068 (11%)
died while receiving catheter dialysis. There were 1,163
(12%) patients who were alive and on catheter dialysis at the
end of the data (12/31/06).
The cohort accounted for 1,075,701 catheter dialysis ses-
sions over the entire observation period (mean 111; median
73; range 7–502) and 218,166 sessions during the ﬁrst eight
weeks of catheter dialysis (mean 22; median 24; range 3–
48; mean per week 3 sessions). There were 1,074,966 (99.9%
of 1,075,701) sessions with a planned BFR between 100
and 500mL/min: 400mL/min (38%); 350mL/min (33%);
300mL/min (13%); <300mL/min (1%). In contrast to
planned BFR, 7% (77,628) had an actual BFR <300mL/min.
There were 70,361 sessions with actual BFR <300mL/min
despite planned BFR ≥300mL/min (catheter dysfunction)
and 6,331 (65.2%) patients had at least one session with
catheter dysfunction (mean = 11.1 sessions; median = 5
sessions).
In the baseline case-crossover analysis (Table 2), using
three case sessions and three control sessions, catheter dys-
function was associated with increased odds of a missed
session due to access problems, an access-related procedure
(both limited and expanded deﬁnition), and either a missed
session due to access problems or an access-related proce-
dure. Catheter dysfunction was associated with increased
odds of all-cause hospitalization in the sensitivity analysis
using one case and one control session, but not in the base-
line analysis.
In the multivariate-repeated measures analysis that
included catheter dysfunction speciﬁed as a dichotomous
variable (BFR < 300mL/min versus ≥300mL/min, the ref-
erence category, Table 3), BFR <300mL/min was associated
with increased odds of a missed session due to access prob-
lems, access-related procedure (limited and expanded deﬁ-
nition), missed session or access-related procedure, and all-
cause hospitalization (odds ratio 1.10; P = 0.001). The
association between catheter dysfunction and dialysis run
time in the same session was not signiﬁcant.
In the multivariate-repeated measures analysis that in-
cluded ﬁve intervals of BFR (100–<150mL/min; 150–
<200mL/min; 200–<250mL/min; 250–<300mL/min;
≥300mL/min, the reference category) and included dialysis
run time in minutes as an independent variable (Table 4),
lower BFR was associated with increased odds of all the
outcomes. With the exception of the odds ratio for hospital-
ization at BFR 250–<300mL/min, all the coeﬃcients were
statistically signiﬁcant (P ≤ 0.05).International Journal of Nephrology 5
Table 1: Demographic and clinical characteristics of the study
population.
Characteristic Frequency %
9,707 100.0%
Age
18–49 2,080 21.43%
50–64 3,073 31.66%
65–74 2,278 23.47%
≥75 2,276 23.45%
Gender
Male 4,587 47.3%
Female 5,120 52.7%
Race
Black 3,903 40.2%
White 5,158 53.1%
Other 646 6.7%
Underlying cause of renal failure
Diabetes 4,456 45.9%
Hypertension 2,678 27.6%
Glomerulonephritis 977 10.1%
Other/unknown 1,596 16.4%
Charlson comorbidity index score
distribution
0 4,038 41.6%
1-2 2,068 21.3%
3-4 2,058 21.2%
≥5 1,543 15.90%
ESRD network∗
01-02 (CT, MA, ME, NH, NY, RI, VT) 458 4.7%
03-04 (DE, NJ, PA) 416 4.3%
05 (DC, MD, VA, WV) 1,018 10.5%
06 & 08 (AL, GA, MS, NC, SC, TN) 1,222 12.6%
07 (FL) 789 8.1%
09-10 (IL, IN, KY, OH) 787 8.1%
11 (MI, MN, ND, SD, WI) 763 7.9%
12 (IA, KS, MO, NE) 375 3.9%
13 (AR, LA, OK) 392 4.0%
14 (TX) 1,095 11.3%
15 (AZ, CO, NM, NV, UT, WY) 581 6.0%
16-17 (AK, CA, HI, ID, MT, NoCA,
OR, WA) 824 8.5%
18 (SoCal) 987 10.2%
∗Abbreviations are US states within each region.
4.Discussion
Using DaVita and USRDS data, we were able to identify a
large cohort of almost 10,000 dialysis patients who received
exclusively catheter dialysis for at least eight weeks between
August 2004 and December 2006. The median duration of
catheterdialysis was longer than 26 weeks, and most patients
switched to a diﬀerent type of access or modality before
December 2006, so we were able to document precisely the
end of uninterrupted catheter use. The proportion of pa-
tients receiving catheter dialysis in this study is consistent
withcurrentpointprevalentestimatesofchroniccatheteruse
in the dialysis population overall.
The patients in our cohort accounted for more than one
million catheter dialysis sessions. We found that approxi-
mately 70,000 sessions, or 7% of those with both a planned
and an actual BFR value present, had an actual BFR
<300mL/min despite a planned BFR ≥300mL/min, a def-
inition of catheter dysfunction that closely approximates
NKF-KDOQI vascular access guidelines. This illustrates that
catheter dysfunction deﬁned according to the BFR threshold
is a common problem, aﬀecting approximately one in 14
sessions or one patient session every month. Almost two
thirds of all patients had at least one session with catheter
dysfunction, and more than 25% of these had at least 12
such sessions, suggesting that catheter dysfunction may be
an ongoing problem in some patients.
Using two diﬀerent analytic approaches, case-crossover
and multivariate-repeated measures analysis, we found
strongassociations betweenthepresenceofcatheterdysfunc-
tion and increased risk of a missed session due to access
problems, access-related procedures, a missed session due to
access problems or access procedure, and all-cause hospital-
ization. In multivariate-repeated measures analysis, when we
changed the speciﬁcation of the catheter dysfunction inde-
pendent variable from dichotomous (BFR < 300mL/min
versus ≥300mL/min) to one that included multiple levels
(100–<150mL/min; 150–<200mL/min; 200–<250mL/min;
250–<300mL/min; ≥300mL/min) and includeddialysis run
time in minutes as an additional independent variable,
we found strong associations between the level of catheter
dysfunction and the odds of the outcome.
Each of these analytic approaches has strengths and lim-
itations. In the case-crossover approach, we included only
patientswhohadtheoutcomeofinterest(e.g.,missedsession
due to access problems). Further, we considered only the
ﬁrst such event for each patient, ignoring those that may
have occurred later in the patient’s catheter dialysis history.
One important advantage of the case-crossover approach is
that patients serve as their own controls because the risk
of “exposure,” in this instance catheter dysfunction in at
least one of three sessions before the event, is compared
during two diﬀerent periods for each individual patient.
Consequently, there is no need to adjust for many of the
factors thatcan confoundassociations between exposureand
outcomes. Case-crossover designs are not immune to prob-
lems of confounding, however, as temporal changes within
patients can confound comparisons between the control and
the case period. We do not believe this was a signiﬁcant issue
in our study since the case and control periods were limited
to a maximum of three dialysis sessions each.
In the multivariate-repeated measures approach, we in-
cluded all patients, all catheter sessions, including those
deﬁned as having dysfunction, and all outcomes events of
interest during the observation period. One limitation of
this approach is that since it includes both patients with and
without at least one session with catheter dysfunction, it6 International Journal of Nephrology
Table 2: Case-crossover analysis of medical services associated with catheter dysfunction.
Type of medical service 3C a s e ∗
sessions
3 Control∗∗
sessions
Odds ratio
(P-value)
1C a s e
session
1 Control
session
Odds ratio
(P-value)
Missed sessiondue to access problems 103 66 1.56 (<0.01) 94 56 1.68 (<0.01)
Access procedure
Limited deﬁnition∗∗∗ 301 234 1.29 (<0.01) 212 179 1.18 (0.10)
Expanded deﬁnition∗∗∗∗ 365 290 1.26 (<0.01) 289 226 1.28 (<0.01)
Missed sessionor access procedure 398 291 1.37 (<0.0001) 321 246 1.30 (<0.01)
Hospitalization (any diagnosis) 395 354 1.12 (0.13) 293 225 1.30 (<0.01)
∗Sessionsimmediately prior to event, that is, sessions 1–3 prior to event.
∗∗Sessions before case sessions,that is, sessions 4–6 prior to event.
∗∗∗Consists of injection for catheter evaluation with ﬂuoroscopy (36598); thrombolytic declotting of catheter (36593); mechanical removal of clot (36596);
mechanical removal of intraluminal(intracatheter) obstructive material (75902); injection of “TPA” (J2997).
∗∗∗∗Consistsofthoseproceduresincludedinthelimiteddeﬁnition,plustunneledcatheterexchangeorreplacement(36581),andthecombinationofremoval
of tunneled catheter (36589) plus tunneled catheter insertion (36558).
Table 3: Repeated measures analysis∗ of medical services associated with catheter dysfunction.
Type of medical service Odds ratio∗∗ 95% conﬁdence interval P-value
Lower Upper
Missed sessiondue to access problems 2.50 2.10 2.97 <0.001
Access procedure
Limited deﬁnition∗∗∗ 2.10 1.97 2.25 <0.001
Expanded deﬁnition∗∗∗∗ 1.17 1.10 1.25 <0.001
Missed sessionor access procedure 2.21 2.11 2.33 <0.001
Hospitalization (any diagnosis) 1.10 1.04 1.17 0.001
∗Multivariateanalysesincludedage,gender,race,underlyingcauseofrenalfailure,dialysisvintage,ESRDNetwork,CharlsonComorbidityIndex,andwhether
the patient was incident to catheter dialysis,as co-variables.
∗∗Odds of medical service before the next dialysis session among those with versus without catheter dysfunction in the preceding session.
∗∗∗Consists of injection for catheter evaluation with ﬂuoroscopy (36598); thrombolytic de-clotting of catheter (36593); mechanical removal of clot (36596);
mechanical removal of intraluminal(intracatheter) obstructive material (75902); injection of “TPA” (J2997).
∗∗∗∗Consistsofthoseproceduresincludedinthelimiteddeﬁnition,plustunneledcatheterexchangeorreplacement(36581),andthecombinationofremoval
of tunneled catheter (36589) plus tunneled catheter insertion (36558).
is necessary to adjust for diﬀerences between patients that
may confound observed associations between catheter dys-
function and medical services. It is possible, therefore, that
observed diﬀerences in patterns of medical services between
those with versus without catheter dysfunction may reﬂect
unobserved diﬀerences in patient characteristics.
Our study has several other limitations. First, our data
source,asinmost retrospective analyses, lackedsome clinical
variables that would have strengthened the study. For exam-
ple, although we sought to characterize catheter dysfunction
according to the most recent NKF-KDOQI guidelines as
“failure to attain and maintain an extracorporeal blood ﬂow
of 300mL/min or greater at a prepump arterial pressure
more negative than −250mmHg,” we did not have access
to information on prepump arterial pressure or whether or
not the patients had undergone line reversal in our dataset.
Although this limited our ability to exactly replicate the
NKF-KDOQIcriteria, the inclusion of blood ﬂow represents
a signiﬁcant clinical focus in assessing a catheter’s ability
to provide an adequate dialysis treatment. Additionally, we
were unable to speciﬁcally identify the brand of catheter, the
precise handling techniques, or the use of locking solution
for each catheter session although presumably most dialysis
sessions would have been conducted under standardized
guidelines as described by DaVita clinical policies and pro-
cedures.Anotherlimitationofthedataisthatwedidnothave
access to a variable indicating dialysis center and included
dialysis Network in lieu of center. Also, to limit false-positive
catheter dysfunction, we restricted our deﬁnition to those
sessions with actual BFR <300mL/min and planned BFR
≥300mL/min, and we set tomissing actualand planned BFR
values <100mL/min. As a result, we have almost certainly
underestimated the number of sessions with catheter dys-
function, and possibly also the eﬀect of catheter dysfunction
on utilization of medical services. These diﬀerences may, in
part, account for the discrepancy between the proportion
of sessions with catheter dysfunction in this study and the
proportion previously reported by CMS [21].
Second, by requiring patients to have at least eight weeks
of catheter dialysis, and to have survived at least 90 days
following the start of dialysis, we have excluded patients who
were on catheter dialysis for shorter periods of time or who
died within 90 days of beginning catheter dialysis. To the
extent that catheter dysfunction is more common sooner
after placement, by excluding patients with short-term cath-
eter dialysis, we may have underestimated the overall rate ofInternational Journal of Nephrology 7
Table 4: Alternative speciﬁcation of catheter dysfunction variable in repeated measures analysis∗ of medical services.
Type of medical service Odds ratio∗∗ 95% conﬁdence interval P-value
Lower Upper
Missed sessiondue to access problems
Blood ﬂow rate ≥ 300mL/min Reference category
100–<150mL/min 8.09 3.75 17.45 <0.001
150–<200mL/min 15.79 11.13 22.40 <0.001
200–<250mL/min 3.14 2.46 4.02 <0.001
250–<300mL/min 1.59 1.22 2.07 0.001
Access procedure
Limited deﬁnition∗∗∗
Blood ﬂow rate ≥ 300mL/min Reference category
100–<150mL/min 4.16 2.80 6.18 <0.001
150–<200mL/min 4.14 3.38 5.08 <0.001
200–<250mL/min 2.45 2.22 2.71 <0.001
250–<300mL/min 1.78 1.63 1.93 <0.001
Expanded deﬁnition∗∗∗∗
Blood ﬂow rate ≥ 300mL/min Reference category
100–<150mL/min 6.88 5.44 8.69 <0.001
150–<200mL/min 5.63 4.88 6.49 <0.001
200–<250mL/min 2.55 2.36 2.75 <0.001
250–<300mL/min 1.72 1.61 1.83 <0.001
Missed sessionor access procedure
Blood ﬂow rate ≥ 300mL/min Reference category
100–<150mL/min 6.98 5.54 8.79 <0.001
150–<200mL/min 5.81 5.05 6.69 <0.001
200–<250mL/min 2.55 2.36 2.74 <0.001
250–<300mL/min 1.72 1.61 1.83 <0.001
Hospitalization(any diagnosis)
Blood ﬂow rate ≥ 300mL/min Reference category
100–<150mL/min 1.59 1.01 2.51 0.05
150–<200mL/min 1.49 1.18 1.87 0.001
200–<250mL/min 1.24 1.13 1.37 <0.001
250–<300mL/min 1.00 0.93 1.08 0.95
∗Multivariate analyses included dialysis run time (minutes), age, gender, race, underlying cause of renal failure, dialysis vintage, ESRD Network, Charlson
Comorbidity Index, and whether the patient was incident to catheter dialysis,as covariables.
∗∗Odds of medical service before the next dialysis session among those with versus without catheter dysfunction in the preceding session.
∗∗∗Consists of injection for catheter evaluation with ﬂuoroscopy (36598); thrombolytic declotting of catheter (36593); mechanical removal of clot (36596);
mechanical removal of intraluminal(intracatheter) obstructive material (75902); injection of “TPA” (J2997).
∗∗∗∗Consistsofthoseproceduresincludedinthelimiteddeﬁnition,plustunneledcatheterexchangeorreplacement(36581),andthecombinationofremoval
of tunneled catheter (36589) plus tunneled catheter insertion (36558).
dysfunction. Catheter dysfunction due to mechanical rea-
sons, which is known to occur sooner rather than later after
placement, may be disproportionately underrepresented.
Also,ifdeathduringtheﬁrst 90daysaftercatheterplacement
is related to serious complications of catheter dysfunction,
such as bloodstream infection, by requiring at least 90 days’
survival, we may have underestimated the impact of catheter
dysfunction on the use of medical services, in particular, on
all-cause hospitalization.
Third, our study population consisted of a point preva-
lent cohort of patients who were receiving dialysis services
at DaVita in August 2004, and who, by deﬁnition, had their
ﬁrst ESRD service before or during that month. We did not
have access to detailed dialysis session data, including type
of dialysis, prior to August 2004. Consequently, we could
not determine the actual start of catheter dialysis for those
who had their ﬁrst ESRD service before the beginning of the
DaVita data and their ﬁrst documented catheter dialysis ses-
sion in August 2004. It is highly likely, however, that some of
these patients began catheterdialysis months before entering
our cohort. Again, to the extent that catheter dysfunction
occurs sooner rather than later following placement, had we8 International Journal of Nephrology
been able to observe all patients from the start of catheter
dialysis, we may have observed a higher rate of dysfunction,
and diﬀerent patterns of medical services.
Finally, we were unableto determine whether the disrup-
tions to dialysis services and the utilization of other medical
services we observed were necessary to ensure adequate
dialysis or an unnecessary response based only on reaching
the BFR threshold in the vascular access guidelines. Dialysis
facilities have strong ﬁnancial incentives to operate at full
capacity, and any missed dialysis session may represent a loss
of revenue for the facility. Also, it seems unlikely that low
BFR alone would be suﬃcient to result in hospitalization.
However, it is more diﬃcult to draw conclusions regarding
other medical services observed in this study, especially in
light of the study by Moist and colleagues that showed BFR
<300mL/min is not an accurate predictor of dialysis inade-
quacy [12].
5.Conclusions
In spite of these limitations, which we believe may have re-
sulted in underestimating both the rate of catheter dysfunc-
tion and the strength of the associations between catheter
dysfunction and use of medical services, we found that
catheter dysfunction deﬁned according to NKF-KDOQI is
common and results in disruptions in the provision of dial-
ysis services and utilization of additional medical services.
Eﬀorts should continue to reduce chronic catheter use, and
to minimize the clinical and economic consequences of
catheter dysfunction through early detection and interven-
tion. Further research would be required to determine the
direct impact of the vascular access guideline onunnecessary
procedures.Ourstudy should be repeated inothercountries,
where the epidemiology and outcomes of catheter dysfunc-
tion may diﬀer from the USA. Also, conducting this study
in patients with arteriovenous ﬁstula or graft would help
validate our ﬁndings on inadequate BFR and outcomes.
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